Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2025 Earnings Presentation
24 slides from Arcticzymes Technologies Asa's earnings presentation, May 8, 2025
Slide 1: Building the Foundation for Profitable Growth
May 8, 2025 CEO Michael Akoh Building the Foundation CFO Børge Sørvoll VP Sales Paul Blackburn for Profitable Growth Q1 2025
Slide 2: Overview
Overview Overview APositioned Norwegian forbiotech withGrowth Profitable growthin Biotech potential A provider of novel Customers are life World class products and Worldclass Products Segment & Customers Talent & Culture Strong Financials Targeting segments with enzymes for advanced science tools co
Slide 3: Agenda
Agenda 1 Highlights Q1, Strategic Priorities and Partnerships 2 Customer Centric Transformation 3 Sales - Biomanufacturing and Molecular Tools 4 Financials 5 Outlook and Q&A
Slide 4: Highlights Q1 2025
Highlights Q1 2025 SAN HQ Record customer Total embedded in AAV base growth lays revenue platform at leading foundation for long 24.9 MNOK CDMO term growth (30.0 MNOK) EBITDA Strong growth in the US Poster presented Performance by acib at -3.7 MNOK Up 25% Y on Y Bioprocessing (3.2 MNOK) Internationa
Slide 5: Strategic priorities
Strategic priorities From Strong Fundamentals to Sustained Growth Short Term Long Term 1 Customer Centric Transformation 1 Develop/commercialize new Molecular Tools enzymes Commercialization – build customer base Sample preparation and amplification Channel development through partners (CDMO/Distrib
Slide 6: Partnership updates
Partnership updates Further Deployment of SAN in CDMO Platforms CDMO platform integration New US CDMO: SAN HQ on their AAV platform in their center of excellence Initial projects expected Q3 CDMO in the UK implemented M-SAN HQ in Lenti viral platform – will transfer to M-SAN HQ GMP once launched Ini
Slide 7: Customer Centric transformation
Customer Centric transformation 7
Slide 8: Building the Path Back to Growth
Building the Path Back to Growth This quarter marks solid progress in our commercial transformation Status Observations Impact Priorities • Focused execution by the • New Projects - customers • Broader reach with deeper • New Customers - driving commercial team actively evaluating and customer engag
Slide 9: Design-in Expanding our customer base
Design-in Expanding our customer base Progression from technical evaluation to commercialisation 9
Slide 10: Broader and deeper opportunity pipeline
Broader and deeper opportunity pipeline Across therapy, diagnostics, and research Customers are progressing through full design-in lifecycles—from technical evaluation to commercialisation Our enzymes are now embedded in platform processes at top-tier contract manufacturers Early-stage research proj
Slide 11: Marketing V2.0
Marketing V2.0 Enhancing customer engagement 9,000 Impressions 14% Engagement 1,000 Clicks Emotional Connection Differentiate 93 Warm/Hot leads Brand recall 2 Metagenomics talks 11
Slide 12: Emerging Opportunities
Emerging Opportunities Metagenomics Potential Market Recent Activity Publications $4.5Bn MG sequencing market by 2028 Highlights the use of M-SAN & SAN Highlights the use of HL-SAN CAGR 17% 12
Slide 13: Sales Update Q1 2025
Sales Update Q1 2025
Slide 14: Q1 Sales — Overview
Q1 Sales — Overview Biomanufacturing and Molecular Tools Sales combined 35 ✓ Quarterly sales of 23.3 MNOK — reflecting a reduction from 30 MNOK in Q1 2024. One large molecular tools 30 customer purchased 9M NOK less this year 25 ✓ NA grew revenues by 20% yoy, APAC grew revenues by 145% yoy and EMEA
Slide 15: Q1 Sales — Biomanufacturing
Q1 Sales — Biomanufacturing Steady Performance with Expanding Customer Base Sales per area 15 ✓ Sales grew 21% to 13.6 MNOK (vs. 11.2 MNOK Q1 2024) — reflecting a strong market presence and commercial momentum ✓ NA grew by 29% YOY; EMEA grew by 12% 10 Sales in MNOK ✓ Biomanufacturing accounts for 58
Slide 16: Q1 Sales — Molecular Tools
Q1 Sales — Molecular Tools Underlying business intact Sales per area 25 20 ✓ Sales at 9.5 MNOK (vs. 18.2 MNOK in Q1 2024) — reflecting the reduction of 9 MNOK from the major 15 Sales in MNOK customer ✓ Molecular Tools accounted for 41% of sales 10 ✓ Strategic focus on Biomanufacturing in 2024, now 5
Slide 17: Q1 2025 – All time high in customer numbers
Q1 2025 – All time high in customer numbers Biomanufacturing traction balancing Molecular Tools shifts Biomanufacturing Q1 Unique customers reached their highest level in recent years, driven by biomanufacturing growth Biomanufacturing Orders increase, customer base continues to grow across NA and E
Slide 18: Expenses & Profitability
® OF Expenses & Profitability ae “X% ge ~e
Slide 19: Profit and loss, Expense development
Profit and loss, Expense development Change in spend as we transform Q1 2025 2024 Personnel expenses Sales revenues 23,3 30,0 Reduction Norwegian personnel Other revenues 1,6 0,0 Sum revenues 24,9 30,0 Increase in US personnel Reduced capitalisation Cost of materials -1,2 -1,0 Change in inventory 0,
Slide 20: Currency impact
USDNOK Currency impact 11,6 11,4 The tide changed in Q1 11,2 11 10,8 10,6 Majority of revenues are in foreign currency 10,4 58% in USD 10,2 10 41% in EURO 9,8 2024 Q1 2025 73% in USD and 27% in EURO for 2024 9,6 EURNOK Currency effect on P&L 12,2 Finance -0.7 MNOK in Q1 (+0.5 increase in Q1 12 2024)
Slide 21: Profitability and expenses
Profitability and expenses Negative impact by currency Sales & EBITDA Q1 2025 2024 Sales revenues 23,3 30,0 Sales 35 Other revenues 1,6 0,0 EBITDA Sum revenues 24,9 30,0 30 Cost of materials -1,2 -1,0 25 Change in inventory 0,3 -0,3 Personnel expenses -18,8 -18,0 20 Other operating expenses -8,9 -8,
Slide 22: Cash flow and short-term investments
Cash flow and short-term investments -1.3 MNOK in changes for Q1* Cash and STI position 280 30 Short term investments (STI) Net Cash (MNOK) 25 260 Changes in Cash and STI (MNOK) 20 240 Changes in cash and STI (MNOK) 15 Net Cash (MNOK) 220 10 200 5 180 0 160 -5 140 -10 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Slide 23: Outlook 2025
Outlook 2025 The market • Opportunities are still plentiful in a dynamic macroeconomic environment • Dialogues with Biomanufacturing customers are many and positive • Still ground to cover – SAN is still new to many Customer centric transformation: • Customer base is expanding – new all time high •
Slide 24: Thank you Q&A
Thank you Q&A arcticzymes.com
ArcticZymes Technologies — Q1 2025 Earnings Presentation on 6ix